Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04190056
Title Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of California, San Francisco
Indications

estrogen-receptor positive breast cancer

Therapies

Pembrolizumab + Tamoxifen

Pembrolizumab + Tamoxifen + Vorinostat

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.